| Description |
Ifetroban is a long-acting thromboxane A2 receptor antagonist, with antiplatelet activity[1].
|
| Related Catalog |
|
| Target |
Thromboxane A2 receptor[1]
|
| In Vitro |
Ifetroban is a long-acting thromboxane/prostaglandin endoperoxide receptor antagonist, with antiplatelet activity[1].
|
| In Vivo |
Ifetroban (20, 40 mg/kg/day, i.p.) shows no effect on the blood pressure in stroke-prone spontaneously hypertensive rats[1]. Ifetroban (BMS 180,291; 1 and 3 mg/kg, p.o.) inhibits aggregation and antagonizes TP-receptor in monekys. Ifetroban (3 mg/kg, i.v.) causes only marginal and transient hemodynamic effects in anesthetized African green monkeys[2].
|
| References |
[1]. Johnson RA, et al. Effect of ifetroban, a thromboxane A2 receptor antagonist, in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens. 1996 Feb;18(2):171-88. [2]. Schumacher WA, et al. Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys. Prostaglandins. 1992 Nov;44(5):389-97.
|
